Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
- References
Chapter 14 - Drugs to Treat Dementia
from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups
Published online by Cambridge University Press: 29 May 2020
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
- References
Summary
Dementia is a clinical syndrome that is estimated to affect 46 million people worldwide. This number is estimated to increase to 131.5 million by 2050 (Prince et al., 2015). Dementia has a huge impact on people with the condition, their families and on health and social services. In the UK alone, it affects some 850 000 people with an estimated annual cost of £26 billion. It is a progressive neuropsychiatric condition leading to a significant strain on individuals, their families and the wider society. The risk increases with age and the burden of disease is set to rise in the coming years (Prince et al., 2015). While symptomatic treatments for the commonest cause of dementia, Alzheimer’s disease, are available, no disease-modifying therapy has emerged and the majority of trials in this space have been negative although there is room for optimism (Aisen, 2017).
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 433 - 453Publisher: Cambridge University PressPrint publication year: 2020